Beam Therapeutics (BEAM) vs Iovance Biotherapeutics (IOVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Iovance Biotherapeutics (IOVA) has outperformed Beam Therapeutics (BEAM) over the past year, gaining 208.0% versus a loss of 5.9%. Over five years, IOVA leads with a -62.7% price change compared with -73.4% for BEAM. Iovance Biotherapeutics is the larger company by market cap ($3.19 billion vs $2.16 billion), about 1.5 times the size, while Beam Therapeutics is growing revenue faster (+120.0% vs +60.6%).
Beam Therapeutics converts more of its revenue into profit, with a net margin of -57.2% versus -148.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BEAM | IOVA |
|---|---|---|
| Share price | $20.90 | $6.90 |
| Market cap | $2.16B | $3.19B |
| 1-day change | -0.19% | -5.61% |
| YTD return | -24.60% | +152.75% |
| 1-year return | -5.90% | +208.04% |
| 5-year return | -73.44% | -62.70% |
| EPS (TTM) | $-0.87 | $-0.49 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $139.74M | $263.50M |
| Revenue growth (YoY) | +120.01% | +60.60% |
| Net income (latest FY) | $-79.99M | $-390.98M |
| Gross margin | — | 34.28% |
| Operating margin | -274.57% | -153.08% |
| Net margin | -57.24% | -148.38% |
| 52-week high | $38.26 | $15.37 |
| 52-week low | $20.44 | $2.08 |
| Distance from 52-week high | -45.37% | -55.11% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +138.52% | +110.14% |
| Average volume | 2.04M | 14.91M |
| Shares outstanding | 103.50M | 462.66M |
| Employees | 557 | 975 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IOVA has outperformed BEAM by 213.9 percentage points over the past year.
- Beam Therapeutics is more profitable, keeping -57.2 cents of every revenue dollar as net income versus -148.4 cents for Iovance Biotherapeutics.
- Beam Therapeutics grew revenue faster in its latest fiscal year (+120.01% vs +60.60%).
About Beam Therapeutics
BEAM stock →Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 557 employees
About Iovance Biotherapeutics
IOVA stock →Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 975 employees
BEAM vs IOVA FAQ
Which is bigger, Beam Therapeutics or Iovance Biotherapeutics?
Iovance Biotherapeutics (IOVA) is larger, with a market capitalization of $3.19B compared with $2.16B for Beam Therapeutics (BEAM).
Which stock has performed better over the past year, BEAM or IOVA?
IOVA returned +208.04% over the past 12 months, compared with -5.90% for BEAM (price return, excluding dividends). Past performance does not predict future results.
Are Beam Therapeutics and Iovance Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.